Single User License
INR 133820
Site License
INR 267640
Corporate User License
INR 401460

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Scar-Pipeline Review, H1 2015

Scar-Pipeline Review, H1 2015

  Request for Sample Report

Executive Summary

Scar-Pipeline Review, H1 2015


Global Markets Direct's, 'Scar-Pipeline Review, H1 2015', provides an overview of the Scar's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Scar

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Scar and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Scar pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Scar

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Scar Overview 9

Therapeutics Development 10

Pipeline Products for Scar-Overview 10

Pipeline Products for Scar-Comparative Analysis 11

Scar-Therapeutics under Development by Companies 12

Scar-Therapeutics under Investigation by Universities/Institutes 14

Scar-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Scar-Products under Development by Companies 18

Scar-Products under Investigation by Universities/Institutes 20

Scar-Companies Involved in Therapeutics Development 21

3M Drug Delivery Systems 21

AlbireoPharma 22

Altacor Ltd. 23

Amakem NV 24

Beech Tree Labs, Inc. 25

Biomolecular Therapeutics GmbH 26

BiOrion Technologies B.V. 27

Clanotech AB 28

Critical Outcome Technologies Inc. 29

Derma Sciences, Inc. 30

Easton Pharmaceuticals Inc. 31

Escape Therapeutics, Inc. 32

EyeGene, Inc. 33

Fibrocell Science, Inc. 34

FirstString Research, Inc. 35

Juventas Therapeutics, Inc. 36

Kasiak Research Pvt. Ltd. 37

Pergamum AB 38

RXi Pharmaceuticals Corporation 39

Symic Biomedical, Inc. 40

Scar-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

A-3914-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

A-5425-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AMA-0526-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

azficel-T-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

BMT-101-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BOT-191-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BTL-slo-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

CLT-28643-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

CM-101-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

decorin-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drug to Agonize Beta 2 Receptor for Wound Scars-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

DSC-127-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

EGS-001-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

EP-003-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

FibroStem-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Granexin-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ICX-RHY-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

JVS-100-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

nefopam hydrochloride-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

PXL-01-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Refaglo-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

RXI-109-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

S-34240-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecules for Wounds and Scars-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecules to Activate SOX-9 for Scar-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

tranilast-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Scar-Recent Pipeline Updates 82

Scar-Dormant Projects 94

Scar-Discontinued Products 95

Scar-Product Development Milestones 96

Featured News & Press Releases 96

Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 96

Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 97

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 97

Feb 03, 2014: RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference 98

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 98

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 99

Jul 15, 2013: FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin Gel for the Treatment of Chronic Wounds and Scar Reduction 99

Jul 12, 2013: RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study 100

Jun 27, 2013: Pergamum Reports Positive Follow-up Data From Phase II Clinical Trial Of PXL-01 For Prevention Of Post-surgical Adhesions 101

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 101

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 103

Disclaimer 104

List of Tables

Number of Products under Development for Scar, H1 2015 10

Number of Products under Development for Scar-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Scar-Pipeline by 3M Drug Delivery Systems, H1 2015 21

Scar-Pipeline by AlbireoPharma, H1 2015 22

Scar-Pipeline by Altacor Ltd., H1 2015 23

Scar-Pipeline by Amakem NV, H1 2015 24

Scar-Pipeline by Beech Tree Labs, Inc., H1 2015 25

Scar-Pipeline by Biomolecular Therapeutics GmbH, H1 2015 26

Scar-Pipeline by BiOrion Technologies B.V., H1 2015 27

Scar-Pipeline by Clanotech AB, H1 2015 28

Scar-Pipeline by Critical Outcome Technologies Inc., H1 2015 29

Scar-Pipeline by Derma Sciences, Inc., H1 2015 30

Scar-Pipeline by Easton Pharmaceuticals Inc., H1 2015 31

Scar-Pipeline by Escape Therapeutics, Inc., H1 2015 32

Scar-Pipeline by EyeGene, Inc., H1 2015 33

Scar-Pipeline by Fibrocell Science, Inc., H1 2015 34

Scar-Pipeline by FirstString Research, Inc., H1 2015 35

Scar-Pipeline by Juventas Therapeutics, Inc., H1 2015 36

Scar-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 37

Scar-Pipeline by Pergamum AB, H1 2015 38

Scar-Pipeline by RXi Pharmaceuticals Corporation, H1 2015 39

Scar-Pipeline by Symic Biomedical, Inc., H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Scar Therapeutics-Recent Pipeline Updates, H1 2015 82

Scar-Dormant Projects, H1 2015 94

Scar-Discontinued Products, H1 2015 95

List of Figures

Number of Products under Development for Scar, H1 2015 10

Number of Products under Development for Scar-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 42

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

3M Drug Delivery Systems


Altacor Ltd.

Amakem NV

Beech Tree Labs, Inc.

Biomolecular Therapeutics GmbH

BiOrion Technologies B.V.

Clanotech AB

Critical Outcome Technologies Inc.

Derma Sciences, Inc.

Easton Pharmaceuticals Inc.

Escape Therapeutics, Inc.

EyeGene, Inc.

Fibrocell Science, Inc.

FirstString Research, Inc.

Juventas Therapeutics, Inc.

Kasiak Research Pvt. Ltd.

Pergamum AB

RXi Pharmaceuticals Corporation

Symic Biomedical, Inc.

Scar Therapeutic Products under Development, Key Players in Scar Therapeutics, Scar Pipeline Overview, Scar Pipeline, Scar Pipeline Assessment

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]